810 related articles for article (PubMed ID: 33414138)
21. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
22. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
[TBL] [Abstract][Full Text] [Related]
23. Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites.
Bezwada D; Brugarolas J
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259915
[TBL] [Abstract][Full Text] [Related]
24. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
[TBL] [Abstract][Full Text] [Related]
25. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Zheng L; Zhang X; Pan X; Huang Z; Zhang M; Xian J; Wei Y; Nie L; Zhang M; Gong J; Chen X; Zhou Q; Zeng H; Chen N
Mod Pathol; 2023 Nov; 36(11):100303. PubMed ID: 37580017
[TBL] [Abstract][Full Text] [Related]
26. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
27. Genetic and epigenetic alterations during renal carcinogenesis.
Arai E; Kanai Y
Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
[TBL] [Abstract][Full Text] [Related]
28. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract][Full Text] [Related]
29. Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors.
Hamza A; Sirohi D; Smith SC; Amin MB
Adv Anat Pathol; 2021 Nov; 28(6):396-407. PubMed ID: 34561376
[TBL] [Abstract][Full Text] [Related]
30. Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP).
Ricketts CJ; Killian JK; Vocke CD; Wang Y; Merino MJ; Meltzer PS; Linehan WM
PLoS One; 2022; 17(12):e0278108. PubMed ID: 36455002
[TBL] [Abstract][Full Text] [Related]
31. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
32. Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study.
Nikolovski I; Carlo MI; Chen YB; Vargas HA
Cancer Imaging; 2021 Feb; 21(1):24. PubMed ID: 33608050
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer.
Ha YS; Chihara Y; Yoon HY; Kim YJ; Kim TH; Woo SH; Yun SJ; Kim IY; Hirao Y; Kim WJ
Urol Int; 2013; 90(2):233-9. PubMed ID: 23295344
[TBL] [Abstract][Full Text] [Related]
34. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
35. Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Iwasaki T; Shibata D; Tomonaga T; Tateishi Y; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Furuya M; Oda Y
Hum Pathol; 2022 Jun; 124():36-44. PubMed ID: 35306021
[TBL] [Abstract][Full Text] [Related]
36. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
[TBL] [Abstract][Full Text] [Related]
37. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
38. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
[TBL] [Abstract][Full Text] [Related]
39. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
40. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
